Abbott Laboratories Q2 Earnings Preview: A Contrarian Buy Opportunity Worth Considering
Summary Abbott Laboratories is upgraded to Buy ahead of Q2 2026 earnings, following a challenging period marked by share price underperformance. The recent acquisition of Exact Sciences adds a high-growth cancer diagnostics vertical, targeting $3bn …